Role of Myokines in Regulating Skeletal Muscle Mass and Function.

Lee JH, Jun HS. · 2019

Read Role of Myokines in Regulating Skeletal Muscle Mass and Function. by Lee JH, Jun HS. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6363662.txt.

Introduction

Lee and Jun present a review in Frontiers in Physiology on myokines, the signals that muscle cells release during contraction. More than 600 such proteins have been found in human muscle cell cultures. Most remain poorly understood, and few have clear links to muscle wasting.

The review focuses on the best-studied myokines and what each one does. Myostatin, the first found, restrains muscle growth through its receptor. Others act within muscle itself or travel to fat, liver, and brain. The authors weigh the evidence on muscle mass and strength for each factor. Their aim is to point toward new treatment targets for muscle loss.

Catalog record

CREATORLee JH, Jun HS.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6363662

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Role of Myokines in Regulating Skeletal Muscle Mass and Function By Jong Han Lee, Hee-Sook Jun Published in: Frontiers in Physiology DOI: 10.3389/fphys.2019.00042 ABSTRACT Abstract Loss of skeletal muscle mass and strength has recently become a hot research topic with the extension of life span and an increasingly sedentary lifestyle in modern society. Maintenance of skeletal muscle mass is considered an essential determinant of muscle strength and function. Myokines are cytokines synthesized and released by myocytes during muscular contractions. They are implicated in autocrine regulation of metabolism in the muscle as well as in the paracrine/endocrine regulation of other tissues and organs including adipose tissue, the liver, and the brain through their receptors. Till date, secretome analysis of human myocyte culture medium has revealed over 600 myokines. In this review article, we summarize our current knowledge of major identified and characterized myokines focusing on their biological activity and function, particularly in muscle mass and function. Keywords: muscular contraction, myocytes, myokines, skeletal muscle mass, muscle strength INTRODUCTION The muscle is a tissue composed of cells or fibers that produce force and movement of the body. They are primarily responsible for maintaining and changing body position, locomotion as well as the movement of internal organs. Different types of muscles perform different functions according to their location and type. Skeletal muscles are one of the most dynamic tissues involved in voluntary contraction according to command (Frontera and Ochala, 2015; Noto and Edens, 2018). They comprise approximately 40% of the total body weight (Frontera and Ochala, 2015; Noto and Edens, 2018). In contrast, cardiac and smooth muscles are associated with involuntary contraction without awareness (Frontera and Ochala, 2015; Hafen and Burns, 2018; Noto and Edens, 2018). Smooth muscles are found throughout the body and tightly regulate many of the body subsystems implicated in maintaining survival (Hafen and Burns, 2018). Myokines are cytokines or peptides synthesized and released by myocytes in muscle tissue in response to muscular contractions (Pedersen et al., 2007). The term “myokine” was first introduced by a Swedish scientist, Bengt Saltin, in 2003 (Pedersen et al., 2003). Myokines are implicated in the autocrine regulation of metabolism in muscles as well as in the para/endocrine regulation of other tissues and organs including the adipose tissue, liver, and brain (Carson, 2017) through their receptors. Since myostatin was first identified as a myokine in 1997, secretome-based analysis of human myocyte culture medium has revealed over 600 myokines till date (Gorgens et al., 2015). However, the majority of these myokines are still not sufficiently characterized. Only few of them have been studied for their biological activity and function and have provided some clear evidence as being released directly from muscle contraction. Moreover, studies potentially associated with muscle atrophy barely exist. Understanding the biological and physiological roles of these myokines in skeletal muscle atrophy or weakness is important and valuable to find novel targets for therapeutic intervention. In this review, we summarize our current knowledge focusing on myokines released directly by muscle contraction and their potential roles associated with skeletal muscle mass and function. MYOSTATIN Myostatin, growth differentiation factor 8, was the first identified myokine in 1997 by Se-Jin Lee and his colleagues (McPherron et al., 1997). It is encoded by the myostatin gene and is known as a highly conserved member of the TGF beta protein family (McPherron et al., 1997). It is abundantly expressed in skeletal muscles, but is also expressed to a lesser extent in cardiac muscles and fat tissues (McPherron et al., 1997; Sharma et al., 1999). Myostatin levels in the plasma of healthy young men has been shown to significantly decrease within 24 h post-exercise when compared to pre-exercise and has also been shown to positively correlate with plasma IL-6 (Kazemi, 2016). In contrast, serum myostatin has been shown to increase in patients with spinal cord injury after aerobic exercise (Han et al., 2016). Although heavily contradicting reports exist on both sides, circulating myostatin shows an obvious increase in females rather than males during sarcopenia (Bergen et al., 2015), and a decrease in cancer-cachexia (Loumaye and Thissen, 2017) and generic neuromuscular disease patients (Awano et al., 2008; Anaya-Segura et al., 2015; Burch et al., 2017). The effects of myostatin are mediated through the activin type IIB receptor (ActRIIB), which is expressed ubiquitously (Pistilli et al., 2011; Amthor and Hoogaars, 2012). The downstream mediators of myostatin, Smad2 and Smad3, are phosphorylated and form a complex with Smad4. This complex in turn stimulates FoxO-dependent transcription and regulates the transcription of genes associated with the proliferation and differentiation in skeletal muscle precursor cells as well as protein degradation pathways (such as the ubiquitin-proteasome processes, and autophagy) in mature myofibers (Burks and Cohn, 2011; Han et al., 2013). In addition, myostatin-mediated Smad signaling activation inhibits protein synthesis in muscle tissues by suppressing the Akt-mediated mTOR signaling pathway (Han et al., 2013). Functionally, myostatin is a negative regulator of muscle growth thereby leading to inhibition of myogenesis through muscle cell differentiation and growth (McPherron et al., 1997). Animals blocking myostatin activity with substance show significantly increased muscle mass (myofiber hypertrophy rather than hyperplasia) (Morvan et al., 2017). In myostatin-knockout mice, the muscle mass is approximately twice increased compared to that in normal mice (McPherron et al., 1997). In humans, individuals with mutations in both copies of the myostatin gene showed significantly increased muscle mass and muscle strength compared to that observed in normal individuals (Schuelke et al., 2004). Growing evidence indicates that increasing myostatin and its analog activin A contribute to the incidence of muscle atrophy (Morvan et al., 2017). Thus, myostatin is considered a promising target molecule for the treatment of muscle wasting. In the past two decades, several agents, such as follistatin (myostatin antagonist), and selective antibody-based approaches targeting ActR-IIB, myostatin, and activin A were developed to antagonize/suppress myostatin signaling. These molecules were evaluated under various pathological conditions such as muscular wasting or atrophy. For example, a myostatin antibody, MYO-029/stamulumab, was tested in broad muscle dystrophic models, including Becker’s muscular dystrophy (BMD) and facioscapulohumeral dystrophy, but failed to show clinical efficacy in elevating muscle strength (Leung et al., 2015). Overexpression of the follistatin isoform, FS344, using an AVV vector showed improved ambulation in patients with BMD and inclusion body myositis (Al-Zaidy et al., 2015; Mendell et al., 2015; Mendell et al., 2017). However, so far none of these treatments have proven to be clinically sufficient as shown in Table 1 (Cohen et al., 2015; Mariot et al., 2017). There are still obstacles (such as lack of target specificity and potential clinical toxicities) to overcome for their use in human patients. In addition, a recent study showed that activin A prominently regulates muscle mass in primates than does myostatin in rodents (Busquets et al., 2012; Cohen et al., 2015), suggesting that targeting myostatin alone may not be sufficient to treat muscle atrophy in humans. [Table: Summary of current trials of myostatin-activin pathway inhibitors.] IRISIN Irisin is a cleaved form of Fibronectin type III domain-containing protein 5 (FNDC5), which was simultaneously discovered by two independent groups in 2002 (Teufel et al., 2002; Colaianni et al., 2014) It was first reported as a potential mediator of the beneficial effect of exercise (Raschke et al., 2013b). Initially, the expression

Read the complete text